News

Euclid Vision Welcomes Specialty Eyecare Professional to Commercial Team

Euclid Vision Corp., a global leader in specialty contact lenses and proactive myopia management initiatives, is pleased to announce the continued expansion of its U.S. sales team with the addition of Jon R. Hudson, ABOC, NCLEC, who has joined the company as account executive for Texas, and Central and Southern U.S. territories. Jon brings 24 years of experience in the eye care industry to his new role.

“We are all very excited to have Jon join our commercial team. The addition of Jon to the U.S. sales force will enable Euclid and Visionary Optics to assist more eye care professionals (ECPs) in providing best-in-class services to more patients, and reinforces our commitment to ECPs and their patients,” said David Bland, Euclid Vision, vice president of sales.

Jon started his career in the eye care industry as a lab technician and optician in both retail and independent eye care practices and followed that by managing independent eye care practices prior to branching off on his own as a practice management consultant. His time with independent practices was focused primarily on maximizing per patient revenue, including the implementation of myopia management programs and initiatives designed to add scleral lenses as a treatment option. Myopia is the leading cause of visual impairment in children worldwide, and its incidence and prevalence are on the rise, with estimates suggesting that more than half of the world’s population will be myopic by 2050. Jon’s passion for myopia management led to his employment with CooperVision Specialty EyeCare, where he held various roles over the course of six years. His primary focus involved development of practice management initiatives for myopia management and training the sales team on implementation of those programs.

Euclid Vision acquired Visionary Optics, a specialty scleral contact lens design and manufacturing pioneer, in 2022. The union of these two companies increases each establishment’s ability to provide comprehensive specialty contact lens care to more patients globally.  “As Euclid Vision and Visionary Optics focus on assisting more ECPs with their efforts to deliver best-in-class specialty contact lens services, in areas such as orthokeratology, scleral, and keratoconus management, Jon’s expansive experience in all sectors of eye care is the perfect fit for our commercial team and the customers we serve in this geographic region,” said Bland.

 

Learn more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and